
June 10 (Reuters) - Gilead Sciences Inc GILD.O:
GILEAD - FDA PLACED A CLINICAL HOLD ON GILEAD’S HIV TREATMENT TRIALS OF GS-1720 AND/OR GS-4182
GILEAD: HOLD DUE TO IDENTIFICATION OF SAFETY SIGNAL OF DECREASES IN CD4+T-CELL & ABSOLUTE LYMPHOCYTE COUNTS IN SUBSET OF PARTICIPANTS GETTING COMBO
GILEAD: INTEND TO INVESTIGATE AND PURSUE POTENTIAL OF BOTH AGENTS AND WORK WITH REGULATORY AUTHORITIES TO RESOLVE ISSUES